Effects of a lifestyle intervention on endothelial function in men on long-term androgen deprivation therapy for prostate cancer

British Journal of Cancer

Volumn 114, Issue 4, 2016, Pages 401-408

  Gilbert, Stephen E ^a   Tew, Garry A ^b   Fairhurst, Caroline ^c   Bourke, Liam ^d   Saxton, John M ^b   Winter, Edward M ^d   Rosario, Derek J ^e  

^a YORK ST JOHN UNIVERSITY   (United Kingdom)

^b NORTHUMBRIA UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF YORK   (United Kingdom)

^d SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

androgen deprivation therapy; cardiovascular disease; endothelial function; exercise; prostatic neoplasm

Indexed keywords

CHOLESTEROL; GONADORELIN AGONIST; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AEROBIC EXERCISE; AGED; ALCOHOL ABSTINENCE; ANDROGEN DEPRIVATION THERAPY; ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE; BODY COMPOSITION; BRACHIAL ARTERY; CALORIC INTAKE; CARBOHYDRATE INTAKE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DIET THERAPY; DIETARY FIBER; EXERCISE; EXERCISE TOLERANCE; EXTERNAL BEAM RADIOTHERAPY; FEEDING BEHAVIOR; FLOW MEDIATED DILATION; FRUIT; HUMAN; LEISURE; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LONG TERM CARE; MALE; MUSCLE MASS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESISTANCE TRAINING; SKELETAL MUSCLE; TREADMILL EXERCISE; TREATMENT DURATION; VASCULAR ENDOTHELIUM; VASODILATATION; VEGETABLE; WALKING; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; DIET; HEALTH BEHAVIOR; LIFESTYLE; METABOLISM; MIDDLE AGED; PROSTATIC NEOPLASMS; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CARDIOVASCULAR DISEASES; DIET; EXERCISE; HEALTH BEHAVIOR; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RISK FACTORS;

EID: 84954341843     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.479     Document Type: Article

References (42)

1. Alibhai SM, Breunis H, Timilshina N, Johnston C, Tomlinson G, Tannock I, Krahn M, Fleshner NE, Warde P, Canning SD, Klotz L, Naglie G. (2010). Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J Clin Oncol. 28: 5038-5045.
2. Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, Cheung AM, Paszat LF. (2009). Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol. 27: 3452-3458.
3. Atkinson G. (2014). Shear rate normalization is not essential for removing the dependency of flow-mediated dilation on baseline artery diameter: past research revisited. Physiol Meas. 35: 1825-1835.
4. Atkinson G, Batterham AM. (2013). The percentage flow-mediated dilation index: a large-sample investigation of its appropriateness, potential for bias and causal nexus in vascular medicine. Vasc Med. 18: 354-365.
5. Atkinson G, Batterham AM, Thijssen DH, Green DJ. (2013). A new approach to improve the specificity of flow-mediated dilation for indicating endothelial function in cardiovascular research. J Hypertens. 31: 287-291.
6. Black MA, Cable NT, Thijssen DH, Green DJ. (2008). Importance of measuring the time course of flow-mediated dilatation in humans. Hypertension. 51: 203-210.
7. Borg GA. (1982). Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 14: 377-381.
8. Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M. (2015). Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-Analysis. Eur Urol. 68: 386-396.
9. Bourke L, Gilbert S, Hooper R, Steed LA, Joshi M, Catto JW, Saxton JM, Rosario DJ. (2014). Lifestyle changes for improving disease-specific quality of life in sedentary men on long-Term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial. Eur Urol. 65: 865-872.
10. Bourke L, Doll H, Crank H, Daley A, Rosario D, Saxton JM. (2011). Lifestyle intervention in men with advanced prostate cancer receiving androgen suppression therapy: a feasibility study. Cancer Epidemiol Biomarkers Prev. 20: 647-657.
11. Brown H, Prescott R. (2006). Applied Mixed Models in Medicine. John Wiley., & Sons: Chichester, West Sussex, UK.
12. Celermajer DS. (1997). Endothelial dysfunction: does it matter?. Is it reversible?. J Am Coll Cardiol. 30: 325-333.
13. Cormie P, Galvão D, Spry N, Joseph D, Chee R, Taaffe D, Chambers SK, Newton R. (2015). Can supervised exercise prevent treatment toxicity in prostate cancer patients initiating androgen deprivation therapy: a randomised controlled trial. BJU Int. 115: 256-266.
14. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D. (2002). Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 39: 257-265.
15. Courneya KS, Friedenreich CM, Quinney HA, Fields AL, Jones LW, Fairey AS. (2004). Predictors of adherence and contamination in a randomized trial of exercise in colorectal cancer survivors. Psychooncology. 13: 857-866.
16. Culos-Reed SN, Robinson JW, Lau H, Stephenson L, Keats M, Norris S, Kline G, Faris P. (2010). Physical activity for men receiving androgen deprivation therapy for prostate cancer: benefits from a 16-week intervention. Support Care Cancer. 18: 591-599.
17. Curran-Everett D. (2013). Explorations in statistics: the analysis of ratios and normalized data. Adv Physiol Educ. 37: 213-219.
18. Deanfield JE, Halcox JP, Rabelink TJ. (2007). Endothelial function and dysfunction: testing and clinical relevance. Circulation. 115: 1285-1295.
19. Edwards DG, Schofield RS, Lennon SL, Pierce GL, Nichols WW, Braith RW. (2004). Effect of exercise training on endothelial function in men with coronary artery disease. Am J Cardiol. 93: 617-620.
20. Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU. (2010). Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol. 28: 340-347.
21. Galvão DA, Spry N, Denham J, Taaffe DR, Cormie P, Joseph D, Lamb DS, Chambers SK, Newton RU. (2014). A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR. Eur Urol. 65: 856-864.
22. Gilbert SE, Tew GA, Bourke L, Winter EM, Rosario DJ. (2013). Assessment of endothelial dysfunction by flow-mediated dilatation in men on long-Term androgen deprivation therapy for prostate cancer. Exp Physiol. 98: 1401-1410.
23. Godin G, Shephard RJ. (1985). A simple method to assess exercise behavior in the community. Can J Appl Sport Sci. 10: 141-146.
24. Gokce N, Vita JA, Bader DS, Sherman DL, Hunter LM, Holbrook M, O'Malley C, Keaney Jr JF, Balady GJ. (2002). Effect of exercise on upper and lower extremity endothelial function in patients with coronary artery disease. Am J Cardiol. 90: 124-127.
25. Green DJ, Jones H, Thijssen D, Cable NT, Atkinson G. (2011). Flow-mediated dilation and cardiovascular event prediction: does nitric oxide matter?. Hypertension. 57: 363-369.
26. Green DJ, Walsh JH, Maiorana A, Best MJ, Taylor RR, O'Driscoll JG. (2003). Exercise-induced improvement in endothelial dysfunction is not mediated by changes in CV risk factors: pooled analysis of diverse patient populations. Am J Physiol Heart Circ Physiol. 285: H2679-H2687.
27. Harville DA. (1977). Maximum likelihood approaches to variance component estimation and to related problems. J Am Stat Assoc. 72: 320-338.
28. Kaminsky LA, Whaley MH. (1998). Evaluation of a new standardized ramp protocol: the BSU/Bruce Ramp protocol. J Cardiopulm Rehabil Prev. 18: 438-444.
29. Nguyen PL, Alibhai SM, Basaria S, D?Amico AV, Kantoff PW, Keating NL, Penson DF, Rosario DJ, Tombal B, Smith MR. (2015). Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 67: 825-836.
30. Nobes JP, Langley SE, Klopper T, Russell-Jones D, Laing RW. (2012). A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int. 109: 1495-1502.
31. Packard GC, Boardman TJ. (1999). The use of percentages and size-specific indices to normalize physiological data for variation in body size: wasted time, wasted effort?. Comp Biochem Physiol A Mol Integr Physiol. 122: 37-44.
32. Parker BA, Trehearn TL, Meendering JR. (2009). Pick your Poiseuille: normalizing the shear stimulus in studies of flow-mediated dilation. J Appl Physiol. 107: 1357-1359.
33. Ras RT, Streppel MT, Draijer R, Zock PL. (2013). Flow-mediated dilation and cardiovascular risk prediction: a systematic review with meta-Analysis. Int J Cardiol. 168: 344-351.
34. Rippe JM, Angelopoulos TJ. (2014). Lifestyle strategies for cardiovascular risk reduction. Curr Atheroscler Rep. 16: 1-7.
35. Schubert M, Joniau S, Gontero P, Kneitz S, Scholz C, Kneitz B, Briganti A, Karnes RJ, Tombal B, Walz J. (2012). The role of adjuvant hormonal treatment after surgery for localized high-risk prostate cancer: results of a matched multiinstitutional analysis. Adv Urol 2012: 612707.
36. Suzuki M, Takamisawa I, Suzuki K, Hiuge A, Horio T, Yoshimasa Y, Harano Y. (2004). Close association of endothelial dysfunction with insulin resistance and carotid wall thickening in hypertension. Am J Hypertens. 17: 228-232.
37. Tanner JM. (1949). Fallacy of per-weight and per-surface area standards, and their relation to spurious correlation. J Appl Physiol. 2: 1-15.
38. Tinken TM, Thijssen DH, Hopkins N, Dawson EA, Cable NT, Green DJ. (2010). Shear stress mediates endothelial adaptations to exercise training in humans. Hypertension. 55: 312-318.
39. Tymchuk CN, Tessler SB, Aronson WJ, Barnard RJ. (1998). Effects of diet and exercise on insulin, sex hormone-binding globulin, and prostate-specific antigen. Nutr Cancer. 31: 127-131.
40. Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelson A, Lambe M, Stattin P, Adolfsson J. (2010). Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol. 28: 3448-3456.
41. Wallace IR, McKinley MC, Bell PM, Hunter SJ. (2013). Sex hormone binding globulin and insulin resistance. Clin Endocrinol (Oxf) 78: 321-329.
42. Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, Tian H, Li P, Niu Y. (2014). Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-Analysis of populationbased observational studies. PLoS One. 9: e107516.